Timetable: Initial (full) marketing authorisation …
The timetables in this document may be subject to revision Initial (Full) Marketing Authorisation application assessment timetables: Assessment of initial submission (120-day timetable)
Download Timetable: Initial (full) marketing authorisation …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
CONSOLIDATED VERSION OF DIRECTIVE …
www.allenovery.comVersion Date – 13 August 2013 00100 23 -0016956 BK:22262888.7 © Allen & Overy 2013 If you have any queries please contact: Matt Huggett
Harmonised Technical Guidance for Non-eCTD …
esubmission.ema.europa.euThis Guidance Document is intended to assist pharmaceutical companies with the submission of regulatory information in electronic format to the National Competent Authorities in the EEA (hereafter referred to as NCAs).
CT authorisation in the EU: present and future
www.ema.europa.euIntroduction of e -application form …Before May 2004. National rules, different processes/requirements for authorisation in each EU Member States …resulted in delays and complications …Regulation (EU) No. 536/2014 (published May 2014) Full harmonisation and combined assessment of multinational trials (after full functionality of the EU
The linguistic review process of product information in ...
www.ema.europa.euThe timeframes apply to initial Marketing Authorisation applications as well as to relevant post-authorisation procedures. The timeframes refer to calendar days, not working days. This document presents the product information linguistic review process within the DMP timeframes and provides details on its practical implementation. 2.
MHRA GMP Data Integrity Definitions and Guidance for ...
assets.publishing.service.gov.ukyears) for records such as batch documents, marketing author isation application data, traceability data for human-derived starting materials (not an exhaustive list). Additionally, at least 2 years of data must be retrievable in a timely manner for the purposes of regulatory inspection.